Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Bentracimab
Therapeutic Area : Hematology
Study Phase : Phase III
Sponsor : Serb
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Through the acquisition, SERB has acquired exclusive US rights to the ticagrelor reversal agent PB2452 (bentracimab), a novel, monoclonal antibody fragment, from SFJ. SFJ will remain responsible for the ongoing trials of bentracimab and will work with SE...
Brand Name : PB2452
Molecule Type : Large molecule
Upfront Cash : Undisclosed
May 11, 2023
Lead Product(s) : Bentracimab
Therapeutic Area : Hematology
Highest Development Status : Phase III
Sponsor : Serb
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Bentracimab
Therapeutic Area : Hematology
Study Phase : Phase III
Recipient : PhaseBio Pharmaceuticals
Deal Size : $120.0 million
Deal Type : Collaboration
Details : PB2452 (bentracimab) is a novel, recombinant, human monoclonal antibody antigen-binding fragment designed to reverse the antiplatelet activity of ticagrelor in major bleeding and urgent surgery situations.
Brand Name : PB2452
Molecule Type : Large molecule
Upfront Cash : Undisclosed
January 17, 2023
Lead Product(s) : Bentracimab
Therapeutic Area : Hematology
Highest Development Status : Phase III
Recipient : PhaseBio Pharmaceuticals
Deal Size : $120.0 million
Deal Type : Collaboration
Lead Product(s) : Pegcetacoplan
Therapeutic Area : Hematology
Study Phase : Phase IV
Recipient : Apellis Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : In the study, EMPAVELI met the primary endpoint, demonstrating superiority to Soliris for the change from baseline in hemoglobin level at Week 16 with an adjusted mean increase of 3.84 g/dL of hemoglobin.
Brand Name : Empaveli
Molecule Type : Peptide
Upfront Cash : Not Applicable
May 14, 2021
Lead Product(s) : Pegcetacoplan
Therapeutic Area : Hematology
Highest Development Status : Phase IV
Recipient : Apellis Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Bempegaldesleukin,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Recipient : Nektar Therapeutics
Deal Size : $150.0 million
Deal Type : Collaboration
Details : The collaboration between SFJ and Nektar will support a new Phase 2/3 registrational clinical study of BEMPEG plus pembrolizumab in patients with head and neck cancer whose tumors express PD-L1 (Combined Positive Score).
Brand Name : NKTR-214
Molecule Type : Large molecule
Upfront Cash : Undisclosed
February 17, 2021
Lead Product(s) : Bempegaldesleukin,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Recipient : Nektar Therapeutics
Deal Size : $150.0 million
Deal Type : Collaboration
Lead Product(s) : PB2452
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase II
Recipient : PhaseBio Pharmaceuticals
Deal Size : $120.0 million
Deal Type : Collaboration
PhaseBio Announces Financing and Co-Development Collaboration with SFJ Pharmaceuticals® for PB2452
Details : The collaboration with SFJ provides PhaseBio with substantial funding to continue the rapid advancement of lead program, PB2452.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
January 10, 2020
Lead Product(s) : PB2452
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase II
Recipient : PhaseBio Pharmaceuticals
Deal Size : $120.0 million
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?